TransMedics Group, Inc. (NASDAQ:TMDX) Shares Acquired by Bank of Montreal Can

Bank of Montreal Can lifted its position in TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) by 17.8% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 82,457 shares of the company's stock after acquiring an additional 12,484 shares during the quarter. Bank of Montreal Can owned 0.25% of TransMedics Group worth $5,141,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in TMDX. Sit Investment Associates Inc. acquired a new position in TransMedics Group in the fourth quarter worth $423,000. Pilgrim Partners Asia Pte Ltd acquired a new position in shares of TransMedics Group in the 4th quarter valued at about $2,494,000. Atlas Capital Advisors Inc. bought a new stake in shares of TransMedics Group during the 4th quarter valued at about $31,000. Pitcairn Co. raised its stake in TransMedics Group by 41.4% during the fourth quarter. Pitcairn Co. now owns 5,646 shares of the company's stock worth $352,000 after acquiring an additional 1,653 shares during the period. Finally, Geode Capital Management LLC lifted its holdings in TransMedics Group by 1.2% in the fourth quarter. Geode Capital Management LLC now owns 772,744 shares of the company's stock worth $48,191,000 after acquiring an additional 8,954 shares during the last quarter. 99.67% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

TMDX has been the subject of several recent research reports. Canaccord Genuity Group reaffirmed a "buy" rating and set a $104.00 target price on shares of TransMedics Group in a report on Tuesday, March 11th. Needham & Company LLC restated a "hold" rating on shares of TransMedics Group in a research report on Wednesday, March 26th. Three equities research analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat, TransMedics Group presently has an average rating of "Moderate Buy" and an average price target of $122.70.

TransMedics Group Price Performance

Shares of TMDX stock traded up $2.86 during midday trading on Friday, reaching $88.24. 971,082 shares of the company were exchanged, compared to its average volume of 1,338,951. The company's 50 day moving average price is $72.08 and its two-hundred day moving average price is $80.28. The company has a market cap of $2.97 billion, a P/E ratio of 93.87 and a beta of 2.14. TransMedics Group, Inc. has a 12 month low of $55.00 and a 12 month high of $177.37. The company has a debt-to-equity ratio of 2.42, a quick ratio of 7.33 and a current ratio of 8.20.

TransMedics Group Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.